0001193125-26-210272
SEC filingNewAmsterdam Pharma reported $3.0M in revenue for Q1 FY2026, up 2.1% year-over-year, reflecting minor adjustments in transaction price estimation under the Menarini collaboration—not commercial scale. Operating loss improved to -$58.4M, driven by reduced operating expenses partially offset by working capital changes.
NewAmsterdam Pharma’s Q1 FY2026 financial results reflect continued execution against its strategic partnership with Menarini and disciplined management of pre-commercial operations. Revenue of $3.0M—up 2.1% year-over-year—stems entirely from collaboration-related activities under the Menarini License, not product sales. As disclosed in the filing, revenue recognition follows an estimate of transaction price that is updated each reporting period using actual cost data and forecasted expenses. This methodology confirms that the modest increase reflects timing or estimation adjustments within a fundamentally flat baseline, not inflection in commercial activity.
Operating income improved to -$58.4M (a 15.2% improvement versus -$68.9M in Q1 FY2025), driven by a reduction in operating expenses for the period. This improvement was partially offset by a change in working capital resulting from a decrease in accrued expenses—a dynamic explicitly cited in the business context packet. Notably, the audit removed unsupported attribution to marketing expense reductions; only the broad driver—reduced operating expenses—remains substantiated.
Net income declined to -$48.4M (a 22.6% deterioration versus -$39.5M in Q1 FY2025), and diluted EPS decreased to -$0.40 (from -$0.34). The widening net loss relative to operating income suggests non-operating factors—including warrant-related adjustments or interest income dynamics—contributed to the variance. The filing notes that interest income was largely driven by a decrease in the amount of cash, cash equivalents and marketable debt securities on which interest is earned, though no specific figures for cash balances or interest income are included in the authoritative packet and therefore cannot be quantified here.
Cash flow from operations used $30.6M, an improvement from $36.5M used in Q1 FY2025. This narrowing reflects the same working capital dynamic—specifically, the decrease in accrued expenses—while continuing to fund ongoing R&D investment. There is no support in the authoritative packet for claims about total cash position, runway duration, or interim analysis timelines; those assertions were removed per audit findings.
In summary, the quarter underscores NewAmsterdam’s operational discipline amid a pre-commercial phase: revenue remains a function of contractual accounting mechanics, not market demand; expense management is progressing; and cash utilization is moderating—but all within the context of sustained investment in obicetrapib’s development path. No forward-looking guidance, milestone expectations, or commercial forecasts are supported by the filed data.